Hsu, P.-C.; Chao, T.-K.; Chou, Y.-C.; Yu, M.-H.; Wang, Y.-C.; Lin, Y.-H.; Lee, Y.-L.; Liu, L.-C.; Chang, C.-C.
AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients. J. Clin. Med. 2021, 10, 4529.
https://doi.org/10.3390/jcm10194529
AMA Style
Hsu P-C, Chao T-K, Chou Y-C, Yu M-H, Wang Y-C, Lin Y-H, Lee Y-L, Liu L-C, Chang C-C.
AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients. Journal of Clinical Medicine. 2021; 10(19):4529.
https://doi.org/10.3390/jcm10194529
Chicago/Turabian Style
Hsu, Po-Chao, Tai-Kuang Chao, Yu-Ching Chou, Mu-Hsien Yu, Yu-Chi Wang, Yi-Hsin Lin, Yi-Liang Lee, Li-Chun Liu, and Cheng-Chang Chang.
2021. "AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients" Journal of Clinical Medicine 10, no. 19: 4529.
https://doi.org/10.3390/jcm10194529
APA Style
Hsu, P.-C., Chao, T.-K., Chou, Y.-C., Yu, M.-H., Wang, Y.-C., Lin, Y.-H., Lee, Y.-L., Liu, L.-C., & Chang, C.-C.
(2021). AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients. Journal of Clinical Medicine, 10(19), 4529.
https://doi.org/10.3390/jcm10194529
